Brokers Offer Predictions for TCRX FY2030 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at HC Wainwright issued their FY2030 EPS estimates for TScan Therapeutics in a research report issued on Wednesday, March 4th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings of ($0.09) per share for the year. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. The firm had revenue of $2.57 million for the quarter. TScan Therapeutics had a negative return on equity of 73.32% and a negative net margin of 1,256.81%.

Several other research firms have also recently commented on TCRX. Wedbush upped their price target on TScan Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd. Finally, Morgan Stanley cut shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research note on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, TScan Therapeutics currently has an average rating of “Hold” and a consensus target price of $6.20.

TScan Therapeutics Stock Up 4.6%

TScan Therapeutics stock opened at $1.13 on Thursday. The stock has a 50 day moving average of $1.06 and a two-hundred day moving average of $1.40. TScan Therapeutics has a twelve month low of $0.88 and a twelve month high of $2.57. The stock has a market capitalization of $64.13 million, a price-to-earnings ratio of -1.13 and a beta of 1.03. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23.

Insiders Place Their Bets

In other news, major shareholder Lynx1 Capital Management Lp acquired 80,069 shares of the company’s stock in a transaction that occurred on Friday, December 19th. The stock was purchased at an average cost of $0.90 per share, with a total value of $72,062.10. Following the purchase, the insider directly owned 7,937,416 shares of the company’s stock, valued at approximately $7,143,674.40. This trade represents a 1.02% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders purchased 161,801 shares of company stock valued at $145,621. Company insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

Several large investors have recently bought and sold shares of TCRX. Panagora Asset Management Inc. acquired a new position in shares of TScan Therapeutics during the 4th quarter worth $25,000. HRT Financial LP purchased a new position in TScan Therapeutics during the 4th quarter valued at about $26,000. Catalyst Funds Management Pty Ltd purchased a new position in TScan Therapeutics during the 2nd quarter valued at about $26,000. Quadrature Capital Ltd acquired a new position in TScan Therapeutics during the second quarter worth about $33,000. Finally, Boothbay Fund Management LLC lifted its holdings in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after purchasing an additional 8,121 shares in the last quarter. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.